Stockreport

Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE

Gritstone bio, Inc.  (GRTS) 
Last gritstone bio, inc. earnings: 11/12 09:01 am Check Earnings Report
PDF -- Preliminary results demonstrate unprecedented levels of primed CD8+ neoantigen-specific cytotoxic T cells and expansion of pre-existing T cells even in low-dose cohor [Read more]